Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sequential Autologous HCT and Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia.

Next Previous
Trial Profile

Sequential Autologous HCT and Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus
  • Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Graft-versus-host disease; Hodgkin's disease; Lymphoid leukaemia; Lymphoproliferative disorders; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use

Most Recent Events

  • 11 Jun 2019 Biomarkers information updated
  • 21 Dec 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
  • 13 Dec 2010 Additional lead trial investigator (Jeanne Palmer) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top